Skip to main
ANRO
ANRO logo

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience Inc has demonstrated significant advancements in its drug candidates, particularly with ALTO-207 (CTC-501), which has shown enhanced tolerability compared to pramipexole, allowing for higher dosing and a faster titration regimen that may improve treatment outcomes for depressive symptoms. The company's revenue for FY24 reached $1.08 billion, marking an approximate 60% increase from the previous fiscal year, highlighting robust financial growth. Additionally, the development of a new transdermal formulation for ALTO-101 has resulted in a better safety profile and favorable pharmacokinetics, supporting ongoing clinical trials and reinforcing confidence in Alto's innovative approach to precision psychiatry.

Bears say

Alto Neuroscience Inc's stock has experienced significant downward pressure following the failure of its lead asset, ALTO-100, in a Phase 2b study for major depressive disorder (MDD) in October 2024, compounded by negative results from ALTO-300. The initial setback raises concerns about the company's direction, as patients with poor memory and cognition typically face greater treatment resistance and worse outcomes, highlighting the challenges in treating depression effectively. Additionally, the ongoing Phase 2b study in bipolar depression, which carries a low probability of success (POS), adds to the skepticism surrounding the viability of the company's clinical programs.

ANRO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ANRO has a Strong Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.